4594 Stock Overview
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
BrightPath Biotherapeutics Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥65.00 |
52 Week High | JP¥185.00 |
52 Week Low | JP¥64.00 |
Beta | 0 |
1 Month Change | -10.96% |
3 Month Change | -21.69% |
1 Year Change | -62.43% |
3 Year Change | -66.67% |
5 Year Change | -77.97% |
Change since IPO | -84.38% |
Recent News & Updates
Recent updates
Shareholder Returns
4594 | JP Biotechs | JP Market | |
---|---|---|---|
7D | -3.0% | -2.0% | 1.0% |
1Y | -62.4% | -23.2% | 38.6% |
Return vs Industry: 4594 underperformed the JP Biotechs industry which returned -23% over the past year.
Return vs Market: 4594 underperformed the JP Market which returned 38.8% over the past year.
Price Volatility
4594 volatility | |
---|---|
4594 Average Weekly Movement | 8.8% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4594's share price has been volatile over the past 3 months.
Volatility Over Time: 4594's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | n/a | Kenichi Nagai | https://www.brightpathbio.com |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
BrightPath Biotherapeutics Co., Ltd. Fundamentals Summary
4594 fundamental statistics | |
---|---|
Market cap | JP¥4.32b |
Earnings (TTM) | -JP¥1.87b |
Revenue (TTM) | JP¥262.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 4594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4594 income statement (TTM) | |
---|---|
Revenue | JP¥262.00m |
Cost of Revenue | JP¥146.00m |
Gross Profit | JP¥116.00m |
Other Expenses | JP¥1.99b |
Earnings | -JP¥1.87b |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
May 10, 2024
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 4594 perform over the long term?
See historical performance and comparison